ImmuCurc

ImmuCurc is a three-active formulation delivered in a delayed-release capsule (Hypromellose + Gellan gum) designed to bypass stomach acid and release in the small intestine where immune-active Peyer's patches are located.

PILLAR 1 — SACCHAROMYCES BOULARDII (≥5 Billion CFU): Non-colonising probiotic yeast. Unlike bacterial probiotics, S. boulardii is naturally resistant to antibiotics and stomach acid. Helps support gut flora balance, mucosal barrier integrity, and secretory IgA production. Does not require refrigeration.

PILLAR 2 — MICRONIZED YEAST β-1,3/1,6-GLUCAN (from S. cerevisiae): Immunomodulatory polysaccharide. This is the active behind the extensive Imuneks clinical dossier (4+ published studies). Key specifications: ≥70% beta-glucan purity, ≥80% particles under 10 microns, from baker's yeast (NOT oat/barley glucan which has no immune activity). Effective dose: only 10–20 mg due to micronization efficiency.

PILLAR 3 — NOVOCURMIN™ MICRONIZED CURCUMIN: Patent-pending micronized curcumin with 89 mg/mL water solubility. Helps support healthy inflammatory response. NF-κB pathway modulation supports balanced immune activation without excessive inflammation.

OTHER INGREDIENTS: Delayed release capsule (Hypromellose, Gellan gum, Yellow iron oxide), Polysorbate 80, Colloidal Silicon Dioxide, Maltodextrin, Stearic Acid, Dicalcium Phosphate.

DELAYED-RELEASE RATIONALE: The Hypromellose + Gellan gum capsule shell resists stomach acid dissolution for approximately 45–60 minutes, releasing contents in the small intestine where: (a) Peyer's patches can directly interact with beta-glucan particles, (b) S. boulardii can colonise the intestinal environment, and (c) curcumin can modulate local inflammatory signalling.

MICRONIZED BETA-GLUCAN — WHY PARTICLE SIZE IS EVERYTHING: Beta-glucan immune activity depends on recognition by Dectin-1 receptors on macrophages in Peyer's patches. Non-micronized beta-glucan particles (>100 µm) aggregate in the GI tract and have limited surface area for receptor engagement. Micronized particles (≥80% under 10 µm) maintain individual particle integrity and maximise Dectin-1 receptor engagement per mg.

DOSE IMPLICATIONS OF MICRONIZATION: Because micronized beta-glucan is so efficiently recognized by immune cells, the effective dose is only 10–20 mg per day. Non-micronized products typically require 250–500 mg or more to achieve comparable immune activation. This is not a marketing claim — it's demonstrated in the published clinical studies where 10 mg micronized beta-glucan produced significant immune outcomes.

NOVOCURMIN CURCUMIN DELIVERY: The curcumin component uses the same Micro Matrix Technology as the standalone NovoCurmin platform — 89 mg/mL water solubility, self-emulsifying matrix, protection from alkaline degradation. In ImmuCurc, this ensures curcumin reaches the intestinal immune tissue in its active form.

INTEGRATED DELIVERY DESIGN: All three actives are co-formulated within the same delayed-release capsule so they arrive at the same intestinal location simultaneously. This is intentional — the immune modulation benefits from all three actives engaging the GALT at the same time rather than at different transit points.

Key takeaway: Micro Matrix Technology in ImmuCurc serves two purposes: (1) micronizing beta-glucan to the optimal particle size for immune receptor engagement, and (2) solubilising curcumin for meaningful absorption at the intestinal level. Both are essential for the formula to work as designed.

The micronized beta-glucan in ImmuCurc has an extensive clinical dossier with MULTIPLE PUBLISHED peer-reviewed studies. These studies were conducted on the micronized beta-glucan component specifically (Imuneks MicroGlucan).

STUDY 1 — RESPIRATORY TRACT INFECTIONS IN CHILDREN (Published): Open-label trial, n=32 children with recurrent RTIs. Daily dose: 10 mg micronized beta-glucan. Results: 81% overall reduction in RTI occurrence. 14/32 children (44%) had ZERO RTIs after supplementation. 26/32 (81%) showed ≥75% reduction in RTI cases/month.

STUDY 2 — MONOCYTE ACTIVATION IN ADVANCED BREAST CANCER (Published): Clinical study in immunosuppressed advanced breast cancer patients. Results: Mean monocyte count increased from 326±124/mm³ to 496±194/mm³ at day 15 (p=0.015). CD95 on CD14+ monocytes: 48.17% to 69.23% (p=0.002). CD45RA on CD14+ monocytes: 49.9% to 61.52% (p=0.001). Demonstrates immune cell activation even in immunocompromised individuals.

STUDY 3 — RECURRENT APHTHOUS STOMATITIS (Published — J. Alternative & Complementary Medicine, 2009): n=79 (37 RAS patients + 42 healthy controls). 27 treated with 10 mg micronized beta-glucan twice daily vs 10 placebo. Results: Significant lymphocyte proliferation improvement (p<0.05). Ulcer Severity Score significantly reduced. 6-month follow-up showed sustained benefit.

STUDY 4 — ALLERGIC RHINITIS / Th1-Th2 BALANCE (Published — European Cytokine Network, 2005): Kirmaz et al. Results: IL-12 increased (p=0.008), IL-4 decreased (p=0.027), IL-5 decreased (p=0.04). Eosinophil percentage significantly decreased. Demonstrates Th1/Th2 immune rebalancing — shifting from allergic (Th2-dominant) toward balanced immune response.

STUDY 5 — ORAL MUCOSITIS IN HEAD & NECK CANCER: Patients receiving chemotherapy. Beta-glucan group (10–20 mg/day) showed less leukocyte decline and significantly lower oral mucositis severity vs control over three chemotherapy cycles. No side effects reported over three months.

STEP 1 — ORAL INGESTION & GASTRIC TRANSIT: Delayed-release capsule protects contents through stomach. Capsule dissolves in small intestine (pH >5.5), releasing micronized beta-glucan particles, S. boulardii, and NovoCurmin curcumin.

STEP 2 — PEYER'S PATCH RECOGNITION: Micronized beta-glucan particles (≥80% under 10 µm) are taken up by M-cells overlying Peyer's patches in the small intestine. M-cells transport particles to the underlying immune tissue (GALT — gut-associated lymphoid tissue).

STEP 3 — DECTIN-1 RECEPTOR ACTIVATION: Macrophages and dendritic cells in Peyer's patches express Dectin-1 receptors that specifically recognize β-1,3/1,6-glucan structures. Binding triggers intracellular signalling cascades (Syk kinase → NF-κB) that activate innate immune responses.

STEP 4 — IMMUNE CELL ACTIVATION CASCADE: Activated macrophages release cytokines (IL-1, IL-6, TNF-α, IL-12) that: Activate NK (Natural Killer) cells for viral/tumour surveillance. Stimulate T-cell differentiation (particularly Th1 pathway). Enhance B-cell antibody production. Prime neutrophils for enhanced phagocytosis. Increase monocyte activity and maturation.

STEP 5 — SYSTEMIC IMMUNE PRIMING: The local GALT activation creates a systemic immune priming effect — enhanced surveillance and response capacity throughout the body, not just in the gut. This is why oral beta-glucan can affect respiratory infections, allergic responses, and even cancer-related immune markers.

CURCUMIN'S ROLE: NovoCurmin curcumin modulates NF-κB signalling to prevent EXCESSIVE immune activation. This creates a balanced response — enhanced immune surveillance without runaway inflammation. The combination of immune activation (beta-glucan) with inflammatory modulation (curcumin) is the key design principle.

CRITICAL DISTINCTION — SOURCE MATTERS: Cereal beta-glucan (oat, barley) is β-1,3/1,4 linked and has NO immune activity — it only helps with cholesterol (different health claim). Baker's yeast beta-glucan is β-1,3/1,6 linked and acts as a potent non-specific immune activator. These are completely different molecules with different biological activities.

WITHIN YEAST BETA-GLUCAN — PARTICLE SIZE DETERMINES ACTIVITY: Non-micronized yeast beta-glucan (>100 microns) aggregates in the GI tract. Aggregated particles have reduced surface area for Dectin-1 engagement. Result: higher doses required (250–500 mg) for modest immune effects.

MICRONIZED ADVANTAGE: Micronized particles (≥80% under 10 µm) maintain individual particle integrity throughout GI transit. Each particle presents maximum surface area to immune receptors. Result: 10–20 mg dose produces significant, published clinical outcomes. This is a 25–50× dose efficiency improvement.

IMUNEKS SPECIFICATIONS: Beta-glucan assay minimum 70%. Total lipid <1%. Total ash <6%. Total protein <3%. Particle size: minimum 80% ≤10 µm. Microbiological count <1000 CFU/g. Cream-white powder. 3+ year stability data. These specifications are what distinguish pharmaceutical-grade micronized beta-glucan from commodity supplements.

COMMERCIAL IMPLICATION: When competing products claim '500 mg beta-glucan,' ask: What source? What linkage? What particle size? What purity? A 500 mg non-micronized oat beta-glucan has ZERO immune activity. A 10 mg micronized yeast β-1,3/1,6-glucan has published clinical evidence of significant immune activation. Dose alone means nothing without these specifications.

APPROVED CLAIMS: 'Supports immune system function' | 'Contains clinically studied micronized beta-glucan with multiple published studies' | 'Designed to support gut-immune health' | 'Delayed-release capsule for targeted intestinal delivery' | 'Contains NovoCurmin™ for enhanced curcumin delivery' | 'Three-pillar immune support formula' | 'Contains S. boulardii probiotic (≥5 Billion CFU)'

PROHIBITED CLAIMS: 'Cures or treats any disease' | 'Prevents cancer' | 'Treats infections' | 'FDA approved' | 'Clinically proven to prevent illness' | 'Guaranteed immune protection' | 'Anti-viral' | 'Prevents COVID/flu' | 'Boosts immunity' (this implies drug-like enhancement)

EVIDENCE DISTINCTION: The clinical studies were conducted on the micronized beta-glucan COMPONENT, not on the complete ImmuCurc formula. You may say 'contains clinically studied beta-glucan' but NOT 'ImmuCurc is clinically proven to reduce infections.' This is a critical compliance boundary.

PREFERRED LANGUAGE: Instead of 'boosts immunity' (implies drug-like action), use 'supports immune function' or 'designed to support the body's natural immune response.' Instead of 'prevents illness,' use 'supports immune system readiness.'

Key takeaway: ImmuCurc has strong component-level evidence (multiple published studies on the beta-glucan). Always distinguish between 'the beta-glucan component has clinical evidence' and 'ImmuCurc as a complete product is clinically proven.' The former is accurate; the latter is not.

Required FDA Disclaimer: 'These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.'